KRAS and neoplasm: Optimisation of ADT-007 led to improved pharmacokinetic properties, generating pro-drug ADT-1004, of inhibiting both MAPK and AKT pathway activation in KRAS G12C, G12D, G12V, and G13Q, and reducing tumour volume in patient or cell line derived xenograft KRas-mutant pancreatic cancer mouse models (Piazza et al., 2024).